Vastagbélrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

3+ intézményből 3, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugália· EU contribution 207 183 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)

  Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spanyolország· EU contribution 194 075 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 217 965 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)

  Paris-Lodron-Universitat Salzburg· Salzburg, Ausztria· EU contribution 4 281 580 EUR· until 2031. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 85 running projects, newest first. Listed amounts together: 233,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

  NCT06006923· Anwaar Saeed· Frissítve: 2026. jan. 20.

  “Terminated per directive from Bayer due to funding.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  NCT04577963· Hutchmed· Frissítve: 2025. júl. 14.

  “At the time of study termination, both fruquintinib and tislelizumab are commercially available in the United States.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  NCT04579757· Hutchmed· Frissítve: 2025. máj. 8.

  “Study terminated by sponsor”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

  NCT04171141· Pfizer· Frissítve: 2025. jan. 16.

  “Study was terminated due to strategic considerations and not due to safety.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

  NCT05690035· Sun Yat-sen University· Frissítve: 2024. júl. 9.

  “Due to slow patient recruiting. No patients were enrolled 12 months after study initiation.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)

  NCT04751955· Korean Cancer Study Group· Frissítve: 2023. okt. 31.

  “This clinical trial was not finally approved by the Korea FDA.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 133
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 317
• Genome-Wide Association Study 65

• Single-cell and spatial transcriptomics define a C3-centred multicellular ecology in colorectal liver metastasis.

  Funct Integr Genomics, 2026. nov.

• Identification of Immuno-Diagnostic and Therapeutic Markers in Tumors and Inflammatory Diseases Based on Single-Cell and Machine Learning Methods.

  Hum Mutat, 2026. okt.

• Resolving cell-cell interaction networks and their molecular logic in complex tissues.

  Nat Methods, 2026. okt.

• Patient-aware single-cell analysis of fibrovascular remodeling in a predominantly colorectal cancer immunotherapy cohort.

  Front Immunol, 2026. okt.

• Vascular Proliferation Index Via a Single-Cell Analysis Is a Superior Prognostic Biomarker to Microvessel Density in Stage II/III Colorectal Cancer.

  Anticancer Res, 2026. okt.

• The dual-enhanced graph learning framework DePass allows paired data integration in single-cell and spatial multiomics.

  Nat Cell Biol, 2026. szept.

• A systematic single-cell analysis of enhancer RNAs across human and mouse.

  Nucleic Acids Res, 2026. szept.

• Characterization of circulating neoantigen-specific T cell responses and public T cell receptors shaping immune memory in Lynch syndrome carriers.

  Cell Rep Med, 2026. szept.

• Integrated single-cell and bulk tissue analyses reveal distinct macrophage subtypes and a candidate prognostic signature in colorectal cancer: implications for tumor immune characterization.

  Front Immunol, 2026. szept.

• Integrated single-cell and spatial transcriptomic analyses reveal malignant epithelial glycolytic heterogeneity and spatial niche remodeling during colorectal cancer progression.

  Funct Integr Genomics, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.